Korean Nationwide Multicenter Pooled Registry of Drug-Eluting Stents
NCT ID: NCT03507205
Last Updated: 2018-04-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
17286 participants
OBSERVATIONAL
2008-04-01
2017-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators will compare EES (Xience V/Promus and Xience Prime), SES (Cypher), ZES (Resolute Integrity, Endeavor Resolute, Endeavor), and BES (Biomatrix, Biomatrix Flex, and Nobori).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Registry to Evaluate the Efficacy of Zotarolimus-Eluting Stent
NCT00960908
Registry to Evaluate Efficacy of Xience/Promus Versus Cypher in Reducing Late Loss After Stenting
NCT00960648
Efficacy and Safety of Xience in Coronary arEry Disease aLL-comers After stENTing Using the PRIME Platform (EXCELLENT-PRIME Registry)
NCT01605721
Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III (LONG-DES-III)
NCT01078038
New Generation Drug Eluting Stent for In-stent Restenosis of Drug Eluting Stent( RESTENT-ISR Trial )
NCT01365572
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HOST-BIOLIMUS-Korea-3000
Active prospective registration of patients receiving biodegradable polymer-coated biolimus-eluting stents (BP-BES; Biomatrix, Biomatrix Flex, Nobori)
Biomatrix; Biomatrix Flex; Nobori
Biodegradable polymer-coated biolimus-eluting stents
EXCELLENT-PRIME
Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents (DP-EES; Xience Prime)
Xience Prime
Durable polymer-coated everolimus-eluting stents
EXCELLENT Prospective cohort
Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents and sirolimus-eluting stents (Xience V/Promus; Cypher)
Xience V/Promus; Cypher
Durable polymer-coated everolimus-eluting stents; Sirolimus-eluting stents
HOST-RESOLINTE
Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES-RI; Resolute Integrity)
DP-ZES-RI
Durable polymer-coated zotarolimus-eluting stents
RESOLUTE-Korea
Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES; Endeavor; Resolute)
Endeavor; Resolute
Durable polymer-coated zotarolimus-eluting stents
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biomatrix; Biomatrix Flex; Nobori
Biodegradable polymer-coated biolimus-eluting stents
Xience Prime
Durable polymer-coated everolimus-eluting stents
Xience V/Promus; Cypher
Durable polymer-coated everolimus-eluting stents; Sirolimus-eluting stents
DP-ZES-RI
Durable polymer-coated zotarolimus-eluting stents
Endeavor; Resolute
Durable polymer-coated zotarolimus-eluting stents
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Alternatively, a legally authorized patient representative may agree to the patient's participation in this study and sign the informed consent form.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hyo-Soo Kim
Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hyo-Soo Kim, MD, PhD
Role: STUDY_CHAIR
Seoul National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wonju Severance Christian Hospital
Wŏnju, Gangwon-do, South Korea
Sejong General Hospital
Bucheon-si, Gyeonggi-do, South Korea
Seoul National University Hospital
Seoul, Jongno-gu, South Korea
Hallym University Sacred Heart Hospital
Anyang, , South Korea
Kosin University Gospel Hospital
Busan, , South Korea
Dankook University Hospital
Cheonan, , South Korea
Soon Chun Hyang University Hospital Cheonan
Cheonan, , South Korea
Chungnam National University Hospital
Daejeon, , South Korea
Chonnam National University Hospital
Gwangju, , South Korea
Gwangju Christian Hospital
Gwangju, , South Korea
Kwangju Veterans Hospital
Gwangju, , South Korea
Chonbuk National University Hospital
Iksan, , South Korea
Wonkwang University Hospital
Iksan, , South Korea
Inje University Ilsan Paik Hospital
Ilsan, , South Korea
National Health Insurance Corporation Ilsan Hospital
Ilsan, , South Korea
Inha University Hospital
Inchon, , South Korea
Chungbuk National University Hospital
Jeonju, , South Korea
Presbyterian Medical Center
Jeonju, , South Korea
Gyeongsang National University Hospital
Jinju, , South Korea
Inje University Pusan Paik Hospital
Pusan, , South Korea
Pusan National University Hospital
Pusan, , South Korea
Bundang CHA Medical Center
Seongnam, , South Korea
Seoul National University Bundang Hospital
Seongnam, , South Korea
Ewha Womans University Medical Center Mokdong Hospital
Seoul, , South Korea
Gangbuk Samsung Hospital
Seoul, , South Korea
Gangnam Severance Hospital
Seoul, , South Korea
Hallym University Kangdong Sacred Heart Hospital
Seoul, , South Korea
Hanyang University Medical Center
Seoul, , South Korea
Korea University Guro Hospital
Seoul, , South Korea
Kyung Hee University Hospital at Gangdong
Seoul, , South Korea
Kyung Hee University Medical Center
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Seoul Boramae Hospital
Seoul, , South Korea
Soonchunhyang University Hospital
Seoul, , South Korea
Yonsei University Medical Center
Seoul, , South Korea
St. Carollo Hospital
Suncheon, , South Korea
Uijeongbu St. Mary's Hospital
Uijeongbu-si, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Park J, Han JK, Kang J, Chae IH, Lee SY, Choi YJ, Rhew JY, Rha SW, Shin ES, Woo SI, Lee HC, Chun KJ, Kim D, Jeong JO, Bae JW, Yang HM, Park KW, Kang HJ, Koo BK, Kim HS. The Clinical Impact of beta-Blocker Therapy on Patients With Chronic Coronary Artery Disease After Percutaneous Coronary Intervention. Korean Circ J. 2022 Jul;52(7):544-555. doi: 10.4070/kcj.2021.0395. Epub 2022 Apr 4.
Hwang D, Park J, Yang HM, Yang S, Kang J, Han JK, Park KW, Kang HJ, Koo BK, Kim HS. Angiographic complete revascularization versus incomplete revascularization in patients with diabetes mellitus. Cardiovasc Diabetol. 2022 Apr 19;21(1):56. doi: 10.1186/s12933-022-01488-7.
Kim M, Park KW, Lee HS, Ki YJ, Kang J, Kim CH, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. The validation of the dual antiplatelet therapy score in East Asians receiving percutaneous coronary intervention with exclusively second generation drug-eluting stents. Catheter Cardiovasc Interv. 2021 Sep;98(3):E332-E341. doi: 10.1002/ccd.29682. Epub 2021 Apr 5.
Kang J, Park KW, Lee HS, Zheng C, Rhee TM, Ki YJ, Chang M, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Relative Impact of Clinical Risk Versus Procedural Risk on Clinical Outcomes After Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2021 Feb;14(2):e009642. doi: 10.1161/CIRCINTERVENTIONS.120.009642. Epub 2021 Feb 5.
Zheng C, Kang J, Yang HM, Han JK, Park KW, Kang HJ, Koo BK, Kim HS. Safety and Efficacy of Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Myocardial Infarction in the Presence of Intracoronary Thrombus: An Analysis From the Grand Drug-eluting Stent Registry. Clin Ther. 2020 May;42(5):954-958.e6. doi: 10.1016/j.clinthera.2020.02.022. Epub 2020 Mar 26.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Grand-DES
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.